Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
The introduction of targeted therapy against CD20+ with the monoclonal antibody rituximab has dramatically improved the survival of B-cell non-Hodgkin lymphoma including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. Unfortunately, CLL remains incurable with chemoimmunotherapy, with...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337412/ |
| id |
pubmed-4337412 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-43374122015-03-02 Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia Cerquozzi, Sonia Owen, Carolyn Review The introduction of targeted therapy against CD20+ with the monoclonal antibody rituximab has dramatically improved the survival of B-cell non-Hodgkin lymphoma including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. Unfortunately, CLL remains incurable with chemoimmunotherapy, with many patients having refractory or relapsing disease after rituximab-containing therapy. Obinutuzumab (GA101) is a novel humanized Type II anti-CD20 monoclonal antibody that has been investigated and compared to rituximab. Here, we provide an overview of obinutuzumab, including its mechanisms of action, preclinical data, and Phase I to III clinical studies. Preclinical data illustrate obinutuzumab’s higher potency compared to rituximab through antibody-dependent cellular cytotoxicity and direct cell death. Recently, the CLL11 study presented a significant benefit from obinutuzumab chemoimmunotherapy and supports its use for treatment-naive unfit CLL patients. Herein, we review that obinutuzumab is both a safe and effective alternative to rituximab. Dove Medical Press 2015-02-16 /pmc/articles/PMC4337412/ /pubmed/25733804 http://dx.doi.org/10.2147/BTT.S61600 Text en © 2015 Cerquozzi and Owen. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Cerquozzi, Sonia Owen, Carolyn |
| spellingShingle |
Cerquozzi, Sonia Owen, Carolyn Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia |
| author_facet |
Cerquozzi, Sonia Owen, Carolyn |
| author_sort |
Cerquozzi, Sonia |
| title |
Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia |
| title_short |
Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia |
| title_full |
Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia |
| title_fullStr |
Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia |
| title_full_unstemmed |
Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia |
| title_sort |
clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia |
| description |
The introduction of targeted therapy against CD20+ with the monoclonal antibody rituximab has dramatically improved the survival of B-cell non-Hodgkin lymphoma including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. Unfortunately, CLL remains incurable with chemoimmunotherapy, with many patients having refractory or relapsing disease after rituximab-containing therapy. Obinutuzumab (GA101) is a novel humanized Type II anti-CD20 monoclonal antibody that has been investigated and compared to rituximab. Here, we provide an overview of obinutuzumab, including its mechanisms of action, preclinical data, and Phase I to III clinical studies. Preclinical data illustrate obinutuzumab’s higher potency compared to rituximab through antibody-dependent cellular cytotoxicity and direct cell death. Recently, the CLL11 study presented a significant benefit from obinutuzumab chemoimmunotherapy and supports its use for treatment-naive unfit CLL patients. Herein, we review that obinutuzumab is both a safe and effective alternative to rituximab. |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337412/ |
| _version_ |
1613191490728624128 |